Invesco PJP and iShares IBB Offer Distinct Risk and Return Profiles

The Invesco Pharmaceuticals ETF (PJP) and the iShares Biotechnology ETF (IBB) present distinct trade-offs for investors seeking exposure to the healthcare sector, with PJP offering lower volatility and higher dividend income against IBB's broader biotechnology focus and lower cost. While both funds are 100% dedicated to healthcare, their structural differences in holdings, fees, and historical performance create different risk and reward profiles.

IBB casts a wide net across 243 biotechnology stocks, whereas PJP focuses on a tighter group of 27 pharmaceutical companies involved in drug development and distribution. The largest positions in IBB include Gilead Sciences, Vertex Pharmaceuticals, and Amgen, while PJP’s top holdings are Gilead Sciences, Pfizer, and AbbVie. IBB was launched in 2001 and has paid $0.34 per share in dividends over the trailing 12 months. PJP was launched in 2005 and has paid $1.13 per share in dividends over the same period.

Costs differ between the two funds. IBB has an expense ratio of 0.44%, meaning investors pay $44 per year for every $10,000 invested. PJP carries a higher expense ratio of 0.58%, equating to $58 per year for every $10,000 invested. This fee structure makes IBB the more affordable option, though PJP provides a higher payout for those seeking passive dividend income.

Risk metrics highlight the volatility gap between the two ETFs. Beta, which measures price volatility relative to the S&P 500 based on monthly returns over up to five years of fund history, is higher for IBB. This suggests IBB is more vulnerable to short-term price fluctuations. During the 2022 bear market, IBB experienced a maximum drawdown of nearly 40%, a downturn that hit the fund much harder than PJP. PJP has generally been more stable in terms of price fluctuations, with a smaller max drawdown and lower beta.

Performance over the past year shows IBB outperforming PJP, driven by surging biotech stocks in 2026. However, PJP has outperformed IBB over the past five years. Rising interest rates and bond yields could potentially hurt some cash-strapped companies, a factor that may influence the performance of these holdings. The choice between the two funds depends on an investor's specific goals and risk tolerance, with IBB suiting those seeking broad biotech exposure and lower fees, while PJP appeals to those prioritizing stability and higher dividends.